

REMARKS

Claims 1-16 and 25 are pending. Claim 1 has been amended, claims 17 to 24 have been canceled.

The claims, as originally filed, are the subject of a restriction requirement pursuant to 35 U.S.C. § 121 and are grouped as follows:

- I. Claims 1-16 and 25, drawn to compounds and compositions containing compounds containing no hetero groups, classified in class 564 subclass 123+.
- II. Claims 1-16 and 25, drawn to compounds and compositions containing compounds containing any hetero group, classified in class 540.
- III. Claims 1-16 and 25, drawn to methods using compounds and compositions containing compounds containing no hetero groups, classified in class 514 subclass 123+.
- IV. Claims 17-24, drawn to methods using compounds and compositions containing compounds containing any hetero group, classified in class 514 subclass 563.

Applicants elect the claims of Group I and further elect the species exemplified in Example 1. Claims 1-16 and 25 all read on the elected species.

Applicants believe the claims are now in condition for examination.

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000



/maureen s gibbons/
Maureen S. Gibbons
Attorney for Applicant
Reg. No. 44,121
Phone: 609-252-3453
Date: February 8, 2007